Sen P, Naveen R, Houshmand N, Kia SM, Joshi M, Saha S, Jagtap K, Agarwal V, Nune A, Nikiphorou E, Tan AL, Shinjo SK, Ziade N, Velikova T, Milchert M, Parodis I, Gracia-Ramos AE, Cavagna L, Kuwana M, Knitza J, Makol A, Patel A, Pauling JD, Wincup C, Barman B, Tehozol EAZ, Serrano JR, De La Torre I, Colunga-Pedraza IJ, Merayo-Chalico J, Chibuzo OC, Katchamart W, Akawatcharangura Goo P, Shumnalieva R, Chen YM, Hoff LS, El Kibbi L, Halabi H, Vaidya B, Shaharir SS, Hasan ATMT, Dey D, Gutierrez CET, Caballero-Uribe CV, Lilleker JB, Salim B, Gheita T, Chatterjee T, Distler O, Saavedra MA, Day J, Chinoy H, Covad Study Grp SA, Kardes S, Kardes SA, Andreoli L, Lini D, Screiber K, Vince MN, Singh YP, Ranjan R, Jain A, Pandya SC, Pilania RK, Sharma A, Manoj MM, Gupta V, Kavadichanda CG, Patro PS, Ajmani S, Phatak S, Goswami RP, Chowdhury AC, Mathew AJ, Shenoy P, Asranna A, Bommakanti KT, Shukla A, Pande AR, Chandwar K, Ghodke A, Boro H, Fazal ZZ, Cansu DU, Yildirim R, Gasparyan AY, Del Papa N, Sambataro G, Fabiola A, Govoni M, Parisi S, Bocci EB, Sebastiani GD, Fusaro E, Sebastiani M, Quartuccio L, Franceschini F, Sainaghi PP, Orsolini G, De Angelis R, Danielli MG, Venerito V, Grignaschi S, Giollo A, Alluno A, Ioannone F, Fornaro M, Traboco LS, Wibowo SAK, Loarce-Martos J, Prieto-Gonzalez S, Gonzalez RA, Yoshida A, Nakashima R, Sato S, Kimura N, Kaneko Y, Gono T, Tomaras S, Proft FN, Holzer MT, Gromova MA, Aharonov O, Griger Z, Hmamouchi I, El Bouchti I, Baba Z, Giannini M, Maurier F, Campagne J, Meyer A, Langguth D, Limaye V, Needham M, Srivastav N, Hudson M, Landon-Cardinal O, Zuleta WGR, Arbelaez A, Cajas J, Silva JAP, Fonseca JE, Zimba O, Bohdana D, Ima-Edomwonyi U, Dedeke I, Airenakho E, Madu NH, Yerima A, Olaosebikan H, Becky A, Koussougbo OD, Palalane E, So H, Ugarte-Gil MF, Chinchay L, Bernaola JP, Pimentel V, Fathi HM, Mohammed RHA, Harifi G, Fuentes-Silva Y, Cabriza K, Losanto J, Colaman N, Cachafeiro-Vilar A, Bautista GG, Ho EJG, Gonzalez R, Nunez LS, Cristian Vergara M, Baez JT, Alonzo H, Pastelin CBS, Salinas RG, Obiols AQ, Chavez N, Ordonez AB, Argueta S, Llerena GAR, Sierra-Zorita R, Arrieta D, Hidalgo ER, Saenz R, Escalante MI, Morales R, Calapaqui W, Quezada I, Arredondo G, Agarwal V, Aggarwal R, Gupta L (2023)
Publication Type: Journal article
Publication year: 2023
DOI: 10.1093/rheumatology/kead057
Objective COVID-19 vaccines have a favorable safety profile in patients with autoimmune rheumatic diseases (AIRDs) such as idiopathic inflammatory myopathies (IIMs); however, hesitancy continues to persist among these patients. Therefore, we studied the prevalence, predictors and reasons for hesitancy in patients with IIMs, other AIRDs, non-rheumatic autoimmune diseases (nrAIDs) and healthy controls (HCs), using data from the two international COVID-19 Vaccination in Autoimmune Diseases (COVAD) e-surveys. Methods The first and second COVAD patient self-reported e-surveys were circulated from March to December 2021, and February to June 2022 (ongoing). We collected data on demographics, comorbidities, COVID-19 infection and vaccination history, reasons for hesitancy, and patient reported outcomes. Predictors of hesitancy were analysed using regression models in different groups. Results We analysed data from 18 882 (COVAD-1) and 7666 (COVAD-2) respondents. Reassuringly, hesitancy decreased from 2021 (16.5%) to 2022 (5.1%) (OR: 0.26; 95% CI: 0.24, 0.30, P < 0.001). However, concerns/fear over long-term safety had increased (OR: 3.6; 95% CI: 2.9, 4.6, P < 0.01). We noted with concern greater skepticism over vaccine science among patients with IIMs than AIRDs (OR: 1.8; 95% CI: 1.08, 3.2, P = 0.023) and HCs (OR: 4; 95% CI: 1.9, 8.1, P < 0.001), as well as more long-term safety concerns/fear (IIMs vs AIRDs - OR: 1.9; 95% CI: 1.2, 2.9, P = 0.001; IIMs vs HCs - OR: 5.4 95% CI: 3, 9.6, P < 0.001). Caucasians [OR 4.2 (1.7-10.3)] were likely to be more hesitant, while those with better PROMIS physical health score were less hesitant [OR 0.9 (0.8-0.97)]. Conclusion Vaccine hesitancy has decreased from 2021 to 2022, long-term safety concerns remain among patients with IIMs, particularly in Caucasians and those with poor physical function.
APA:
Sen, P., Naveen, R., Houshmand, N., Kia, S.M., Joshi, M., Saha, S.,... Gupta, L. (2023). Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys. Rheumatology. https://doi.org/10.1093/rheumatology/kead057
MLA:
Sen, Parikshit, et al. "Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys." Rheumatology (2023).
BibTeX: Download